What is Alexander disease, including its genetic cause, typical clinical presentation, and recommended management?

Alexander Disease

Alexander disease is a rare, fatal genetic leukodystrophy caused by mutations in the GFAP gene, characterized by progressive neurological deterioration with distinct age-dependent presentations: infantile forms present with macrocephaly, seizures, and developmental regression, while adult-onset forms manifest with bulbar dysfunction, ataxia, and pyramidal signs. 1

Genetic Cause

Alexander disease results from heterozygous mutations in the GFAP gene (glial fibrillary acidic protein), representing the first identified primary genetic disorder of astrocytes 1. Over 750 disease-causing mutations have been identified, with no clear genotype-phenotype correlation 2. The pathogenic mechanism involves:

• GFAP overexpression correlating with disease severity 3
• Accumulation of abnormal GFAP protein in astrocytes
• Formation of Rosenthal fibers (cytoplasmic inclusions containing GFAP and heat-shock proteins) - the pathological hallmark 1
• Progressive astrocyte dysfunction leading to white matter and brainstem degeneration

Inheritance is autosomal dominant with variable expressivity, though most cases appear sporadic due to de novo mutations 4, 5.

Clinical Presentation by Age

Infantile-Onset (Most Common in Children)

• Macrocephaly (enlarged head)
• Seizures (often presenting symptom)
• Psychomotor retardation and developmental delays 1
• Progressive leukoencephalopathy (white matter disease)
• Death typically within the first decade 1

Adult-Onset (Increasingly Recognized)

Onset can occur as late as the 7th decade (age 62-71 documented) 4. The clinical triad includes:

1. Bulbar dysfunction (most frequent, though often not at onset):

   • Dysarthria (speech difficulty)
   • Dysphagia (swallowing difficulty)
   • Dysphonia (voice changes)
   • Palatal myoclonus (highly suggestive when present) 4

2. Pyramidal signs (7/11 patients in one series):

   • Spasticity
   • Hyperreflexia
   • Weakness 4

3. Cerebellar ataxia (7/11 patients):

   • Gait instability
   • Coordination problems 4

Additional features:

• Sleep disorders (common) 4
• Dysautonomia and urinary disturbances 4
• Oculomotor dysfunction 5
• Fluctuating course possible 4
• Slowly progressive, less severe than infantile forms 4

Critical Diagnostic Pitfall

Misdiagnosis at presentation is frequent in adult-onset cases due to non-specific symptoms mimicking other neurodegenerative conditions 4. Two patients in one series were completely asymptomatic despite having the mutation 4.

Diagnostic Approach

Neuroimaging (Essential for Diagnosis)

MRI is instrumental in suggesting the correct diagnosis and shows characteristic findings in adult-onset disease 4:

Pathognomonic features:

• Atrophy of the medulla oblongata extending caudally to cervical spinal cord (present in ALL cases) 4
• Reduced sagittal diameter of the medulla oblongata 6
• Garland-like (periventricular) T2/FLAIR hyperintense rim along lateral ventricular walls 5, 6

Infantile forms show:

• Extensive cerebral white matter involvement
• Frontal predominance of leukoencephalopathy 3

Genetic Confirmation

Sequence analysis of the GFAP gene is required for definitive diagnosis 1, 4:

1. Sanger sequencing identifies most pathogenic variants 6
2. Test for heterozygous missense mutations in GFAP coding region
3. No mutation found does not exclude diagnosis - one typical patient carried only a rare polymorphism (p.D157N) 4
4. In silico prediction tools help assess pathogenicity of novel variants 5

When to Suspect Alexander Disease

Consider Alexander disease in any patient of any age presenting with lower brainstem signs, particularly:

• Unexplained bulbar dysfunction with brainstem atrophy on MRI 7, 4
• Palatal myoclonus (strongly suggestive) 4
• Progressive ataxia with pyramidal signs and medullary atrophy 5
• Family history may be misleading due to variable expressivity 4

Management Recommendations

Current Treatment Limitations

No disease-modifying therapy is currently available 8. Management is entirely supportive and symptomatic:

Symptomatic interventions:

• Speech therapy for dysarthria
• Swallowing evaluation and dietary modifications for dysphagia
• Gastrostomy tube placement when dysphagia becomes severe
• Physical therapy for spasticity and mobility
• Antiepileptic drugs for seizures (infantile forms)
• Sleep disorder management 4

Prognosis

• Infantile forms: fatal, typically within first decade 1
• Adult-onset forms: variable course, usually slowly progressive with longer survival than early-onset disease 4
• Adult-onset Alexander disease may be the most common form of the disease, contrary to historical understanding 4

Future Therapeutic Directions

Clinical trials are exploring GFAP gene knockout strategies 8. However, because GFAP plays a neuroprotective role in brain injury and stress, alternative approaches targeting downstream pathways (STAT3, GDNF, NF-κB, LCN-2) are being investigated to downregulate rather than eliminate GFAP expression 8.

Genetic Counseling

Essential for all confirmed cases:

• Autosomal dominant inheritance pattern with variable expressivity 5
• 50% recurrence risk for offspring of affected individuals
• Presymptomatic testing available for at-risk family members
• Asymptomatic carriers exist - genetic testing may identify individuals before symptom onset 4

Early recognition through characteristic MRI findings enables timely genetic testing, appropriate symptomatic management, and informed family counseling 7, 5.